TNM staging of non-small cell lung cancer: Comparison of PET/MR and PET/CT

Journal of Nuclear Medicine

Volumn 57, Issue 1, 2016, Pages 21-26

  Huellner, Martin W ^a   Galiza Barbosa, Felipe De ^a   Husmann, Lars ^a   Pietsch, Carsten M ^a   Mader, Cäcilia E ^a   Burger, Irene A ^a   Stolzmann, Paul ^a   Delso, Gaspar ^a,b   Frauenfelder, Thomas ^a   Von Schulthess, Gustav K ^a   Veit Haibach, Patrick ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GE HEALTHCARE   (United States)

Author keywords

Lung; Oncology; PET CT; PET MR; TNM stage

Indexed keywords

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; EXTRATHORACIC METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; MALE; METASTASIS; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; THORAX SURGERY; WHOLE BODY IMAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; LUNG NEOPLASMS; MULTIMODAL IMAGING; OBSERVER VARIATION; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84958679685     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.115.162040     Document Type: Article

References (29)

1. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
2. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e211S-50S.
3. Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014;12:1738-1761.
4. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845-855.
5. Huellner MW, Appenzeller P, Kuhn FP, et al. Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. Radiology. 2014;273:859-869.
6. Fraioli F, Screaton NJ, Janes SM, et al. Non-small-cell lung cancer resectability: diagnostic value of PET/MR. Eur J Nucl Med Mol Imaging. 2015;42:49-55.
7. Catalano OA, Rosen BR, Sahani DV, et al. Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients-a hypothesis-generating exploratory study. Radiology. 2013;269:857-869.
8. Ohno Y, Koyama H, Yoshikawa T, et al. Three-way comparison of whole-body MR, coregistered whole-body FDG PET/MR, and integrated whole-body FDG PET/CT imaging: TNM and stage assessment capability for non-small cell lung cancer patients. Radiology. 2015;275:849-861.
9. 18F-FDG PET/CT. J Nucl Med. 2014;55:373-378.
10. Yi CA, Shin KM, Lee KS, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248:632-642.
11. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008;248:643-654.
12. Plathow C, Aschoff P, Lichy MP, et al. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer: initial results. Invest Radiol. 2008;43:290-297.
13. Kuhn FP, Hullner M, Mader CE, et al. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed? J Nucl Med. 2014;55:551-558.
14. Appenzeller P, Mader C, Huellner MW, et al. PET/CT versus body coil PET/MRI: how low can you go? Insights Imaging. 2013;4:481-490.
15. Pipe JG. Motion correction with PROPELLER MRI: application to head motion and free-breathing cardiac imaging. Magn Reson Med. 1999;42:963-969.
16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th ed. of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
18. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl 6):vi89-98.
19. Ohno Y, Adachi S, Motoyama A, et al. Multiphase ECG-triggered 3D contrastenhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging. 2001;13:215-224.
20. Hochhegger B, Marchiori E, Sedlaczek O, et al. MRI in lung cancer: a pictorial essay. Br J Radiol. 2011;84:661-668.
21. Stolzmann P, Veit-Haibach P, Chuck N, et al. Detection rate, location, and size of pulmonary nodules in trimodality PET/CT-MR: comparison of low-dose CT and Dixon-based MR imaging. Invest Radiol. 2013;48:241-246.
22. Ohno Y, Koyama H, Nogami M, et al. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. J Magn Reson Imaging. 2007;26:1071-1080.
23. Al-Nabhani KZ, Syed R, Michopoulou S, et al. Qualitative and quantitative comparison of PET/CT and PET/MR imaging in clinical practice. J Nucl Med. 2014;55:88-94.
24. Hendriks LE, Bootsma GP, de Ruysscher DK, et al. Screening for brain metastases in patients with stage III non-small cell lung cancer: is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain? Lung Cancer. 2013;80:293-297.
25. Lee HY, Lee KS, Kim BT, et al. Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci. 2009;24:1132-1138.
26. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol. 2005;40:743-753.
27. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardio-Thorac Surg. 2014;45:787-798.
28. Vansteenkiste J, Crino L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462-74.
29. Beiderwellen K, Huebner M, Heusch P, et al. Whole-body [18F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: initial results. Eur Radiol. 2014;24:2023-2030.